Rubicon Research’s Satara manufacturing facility received one procedural observation in Form 483 following an unannounced US FDA inspection conducted from October 5 to 9.
Rubicon Research’s Satara manufacturing facility received one procedural observation in Form 483 following an unannounced US FDA inspection conducted from October 5 to 9.